Semaglutide

Semaglutide is a long-acting analog of native GLP-1(7-37) with two structural modifications that drive its pharmacology: an Aib substitution at position 8 confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation, and a C18 fatty diacid attached via a γGlu-2xOEG spacer at Lys26 mediates reversible albumin binding for a circulating half-life of approximately seven days.

At the GLP-1 receptor, semaglutide drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and activates arcuate POMC/CART neurons in the hypothalamus that regulate satiety and energy intake. Central nervous system penetration is limited but functionally sufficient to engage hindbrain and hypothalamic GLP-1R populations relevant to appetite regulation.

Compared to liraglutide, the longer half-life produces flatter pharmacokinetics and steadier receptor occupancy. Compared to tirzepatide, semaglutide lacks GIP receptor activity — a distinction relevant to mechanism discussions in metabolic research.

Research Applications

• Reference compound for GLP-1 receptor pharmacology in metabolic and endocrinology research.
• Comparator in dual and triple incretin agonist development programs.
• Studies of central GLP-1 signaling in hypothalamic and hindbrain satiety circuits.
• Cardiovascular and renal outcome research in metabolic disease models.